Cargando…
Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety
OBJECTIVE: Angiotensin II is an endogenous hormone with vasopressor and endocrine activities. This is a systematic review of the safety of IV angiotensin II. DATA SOURCES: PubMed, Medline, Scopus, and Cochrane. STUDY SELECTION: Studies in which human subjects received IV angiotensin II were selected...
Autores principales: | Busse, Laurence W., Wang, Xueyuan Shelly, Chalikonda, Divya M., Finkel, Kevin W., Khanna, Ashish K., Szerlip, Harold M., Yoo, David, Dana, Sharon L., Chawla, Lakhmir S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515638/ https://www.ncbi.nlm.nih.gov/pubmed/28489648 http://dx.doi.org/10.1097/CCM.0000000000002441 |
Ejemplares similares
-
Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020) -
The use of angiotensin II in distributive shock
por: Chawla, Lakhmir S., et al.
Publicado: (2016) -
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
por: Tumlin, James A., et al.
Publicado: (2018) -
Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
por: Ham, Kealy R., et al.
Publicado: (2019) -
Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
por: Chawla, Lakhmir S, et al.
Publicado: (2014)